CoChat

A Novel Role of Sodium Butyrate in the Regulation of Cancer-associated Aromatase Promoters I.3 and II by Disrupting a Transcriptional Complex in Breast Adipose Fibroblasts

Open access
Deb, Santanu, Zhou, Jianfeng, Amin, Sanober A., Imir, Ayse Gonca, Yilmaz, Mehmet Bertan, Lin, Zihong, Bulun, Serdar E. · 2006 · Journal of Biological Chemistry
Cited by 46

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

The aromatase gene encodes the key enzyme for estrogen formation. Aromatase enzyme inhibitors eliminate total body estrogen production and are highly effective therapeutics for postmenopausal breast cancer. A distal promoter (I.4) regulates low levels of aromatase expression in tumor-free breast adipose tissue. Two proximal promoters (I.3/II) strikingly induce in vivo aromatase expression in breast fibroblasts surrounding malignant cells. Treatment of breast fibroblasts with medium conditioned with malignant breast epithelial cells (MCM) or a surrogate hormonal mixture (dibutyryl (Bt2)cAMP plus phorbol diacetate (PDA)) induces promoters I.3/II. The mechanism of promoter-selective expression, however, is not clear. Here we reported that sodium butyrate profoundly decreased MCM- or Bt2cAMP + PDA-induced promoter I.3/II-specific aromatase mRNA. MCM, Bt2cAMP + PDA, or sodium butyrate regulated aromatase mRNA or activity only via promoters I.3/II but not promoters I.1 or I.4 in breast, ovarian, placental, and hepatic cells. Mechanistically, recruitment of phosphorylated ATF-2 by a CRE (-211/-199, promoter I.3/II) conferred inductions by MCM or Bt2cAMP + PDA. Chromatin immunoprecipitation-PCR and immunoprecipitation-immunoblotting assays indicated that MCM or Bt2cAMP + PDA stabilized a complex composed of phosphorylated ATF-2, C/EBPbeta, and cAMP-response element-binding protein (CREB)-binding protein in the common regulatory region of promoters I.3/II. Overall, histone acetylation patterns of promoters I.3/II did not correlate with sodium butyrate-dependent silencing of promoters I.3/II. Sodium butyrate, however, consistently disrupted the activating complex composed of phosphorylated ATF-2, C/EBPbeta, and CREB-binding protein. This was mediated, in part, by decreased ATF-2 phosphorylation. Together, these findings represent a novel mechanism of sodium butyrate action and provide evidence that aromatase activity can be ablated in a signaling pathway- and cell-specific fashion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m508498200

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 50

  1. Paridaens, 2003, Ann. Oncol., 14, 1391, 10.1093/annonc/mdg362 · DOI · Paper page
  2. Baum, 2002, Lancet, 359, 2131, 10.1016/S0140-6736(02)09088-8 · DOI · Paper page
  3. Ellis, 2003, J. Steroid Biochem. Mol. Biol., 86, 301, 10.1016/S0960-0760(03)00371-6 · DOI
  4. Geisler, 2003, J. Steroid Biochem. Mol. Biol., 86, 245, 10.1016/S0960-0760(03)00364-9 · DOI
  5. Miller, 2001, J. Steroid Biochem. Mol. Biol., 79, 93, 10.1016/S0960-0760(01)00148-0 · doi:10.1016/s0960-0760(01)00148-0
  6. Miller, 2003, J. Steroid Biochem. Mol. Biol., 86, 413, 10.1016/S0960-0760(03)00352-2 · DOI
  7. Simpson, 2001, Ann. N. Y. Acad. Sci., 949, 58, 10.1111/j.1749-6632.2001.tb04002.x · DOI · Paper page
  8. Ackerman, 1981, J. Clin. Endocrinol. Metab., 53, 412, 10.1210/jcem-53-2-412 · DOI · Paper page
  9. Price, 1992, J. Clin. Endocrinol. Metab., 74, 1247
  10. James, 1990, Ann. N. Y. Acad. Sci., 595, 227, 10.1111/j.1749-6632.1990.tb34296.x · DOI
  11. O'Neill, 1988, Br. Med. J., 296, 741, 10.1136/bmj.296.6624.741 · DOI · Paper page
  12. Bulun, 1993, J. Clin. Endocrinol. Metab., 77, 1622
  13. Yue, 1998, Cancer Res., 58, 927
  14. Mahendroo, 1993, J. Biol. Chem., 268, 19463, 10.1016/S0021-9258(19)36538-X · DOI · Paper page
  15. Zhao, 1995, Mol. Endocrinol., 9, 340
  16. Agarwal, 1996, J. Clin. Endocrinol. Metab., 81, 3843
  17. Zhou, 1996, J. Steroid Biochem. Mol. Biol., 59, 163, 10.1016/S0960-0760(96)00100-8 · DOI
  18. Harada, 1997, J. Steroid Biochem. Mol. Biol., 61, 175, 10.1016/S0960-0760(97)80010-6 · DOI
  19. Zhou, 1999, Arch. Biochem. Biophys., 371, 179, 10.1006/abbi.1999.1454 · DOI
  20. Zhao, 1996, Endocrinology, 137, 5739, 10.1210/endo.137.12.8940410 · doi:10.1210/endo.137.12.8940410 · Paper page
  21. Zhou, 2001, Cancer Res., 61, 2328
  22. Harada, 1998, Breast Cancer Res. Treat., 49, S15, 10.1023/A:1006076101178 · DOI
  23. McIntyre, 1991, Gastroenterology, 101, 1274, 10.1016/0016-5085(91)90077-X · DOI
  24. Weidle, 2000, Anticancer Res., 20, 1471
  25. Gore, 2000, Exp. Opin. Investig. Drugs, 9, 2923, 10.1517/13543784.9.12.2923 · DOI · Paper page
  26. Sowa, 2003, Nippon Eiseigaku Zasshi, 58, 267, 10.1265/jjh.58.267 · DOI
  27. Cuisset, 1997, J. Biol. Chem., 272, 24148, 10.1074/jbc.272.39.24148 · DOI
  28. Nichols, 1995, J. Soc. Gynecol. Investig., 2, 45, 10.1177/107155769500200109 · doi:10.1177/107155769500200109
  29. Zhao, 1995, J. Biol. Chem., 270, 16449, 10.1074/jbc.270.27.16449 · DOI · Paper page
  30. Meng, 2001, Cancer Res., 61, 2250
  31. Gurates, 2003, Mol. Cell. Endocrinol., 208, 61, 10.1016/S0303-7207(03)00198-9 · DOI
  32. Bulun, 1993, J. Clin. Endocrinol. Metabol., 77, 1616
  33. Cleland, 1983, Endocrinology, 113, 2155, 10.1210/endo-113-6-2155 · DOI · Paper page
  34. Hecht, 1996, Nature, 383, 92, 10.1038/383092a0 · DOI · Paper page
  35. Cosma, 1999, Cell, 97, 299, 10.1016/S0092-8674(00)80740-0 · DOI · Paper page
  36. Shaywitz, 1999, Annu. Rev. Biochem., 68, 821, 10.1146/annurev.biochem.68.1.821 · DOI · Paper page
  37. Simpson, 1994, Endocr. Rev., 15, 342
  38. Michael, 1997, Mol. Cell. Endocrinol., 134, 147, 10.1016/S0303-7207(97)00178-0 · DOI
  39. Jin, 2000, Breast Cancer Res. Treat., 62, 151, 10.1023/A:1006481228794 · DOI
  40. Zhou, 1998, Arch. Biochem. Biophys., 353, 213, 10.1006/abbi.1998.0641 · DOI
  41. Montminy, 1997, Annu. Rev. Biochem., 66, 807, 10.1146/annurev.biochem.66.1.807 · DOI · Paper page
  42. Maekawa, 1989, EMBO J., 8, 2023, 10.1002/j.1460-2075.1989.tb03610.x · DOI · Paper page
  43. Lee, 2001, Biochem. Biophys. Res. Commun., 281, 1241, 10.1006/bbrc.2001.4494 · DOI
  44. Shuman, 1997, J. Biol. Chem., 272, 12793, 10.1074/jbc.272.19.12793 · DOI · Paper page
  45. Mink, 1997, Mol. Cell. Biol., 17, 6609, 10.1128/MCB.17.11.6609 · DOI · Paper page
  46. Boffa, 1981, J. Biol. Chem., 256, 9612, 10.1016/S0021-9258(19)68806-X · DOI · Paper page
  47. Jung, 2005, Cancer Lett., 225, 199, 10.1016/j.canlet.2004.11.029 · DOI
  48. Cuisset, 1998, Biochem. Biophys. Res. Commun., 246, 760, 10.1006/bbrc.1998.8698 · DOI
  49. Schwartz, 1998, Mol. Cell. Biochem., 188, 21, 10.1023/A:1006831330340 · DOI
  50. Vernia, 2000, Dig. Dis. Sci., 45, 976, 10.1023/A:1005537411244 · DOI

Cited by

Metadata

Authors
Deb, S., Zhou, J., Amin, S. A., Imir, A. G., Yilmaz, M. B., Lin, Z., & Bulun, S. E.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2006-02
Volume
281
Issue
5
Pages
2585-2597
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2100392901
Cited by
46
References
9
FWCI
2.18
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.